NCT01043172View on ClinicalTrials.gov

A Study of Gemcitabine as an Adjuvant Treatment for Cholangiocarcinoma After Surgical Resection

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

July 20, 2009

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Cholangiocarcinoma
Interventions
DRUG

Gemcitabine

Gemcitabine : 1000 mg/m2/day D1,8,15 Repeated every 4 weeks 6 cycles

Trial Locations (1)

410-769

National Cancer Center, Goyang-si

Sponsors
All Listed Sponsors
collaborator

Dong-A Pharmaceutical Co., Ltd.

INDUSTRY

lead

National Cancer Center, Korea

OTHER_GOV